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PURPOSE. The role of R-Ras in retinal angiogenesis and vascular permeability was evaluated in
an oxygen-induced retinopathy (OIR) model using R-Ras knockout (KO) mice and in human
diabetic neovascular membranes.
METHODS. Mice deficient for R-Ras and their wild-type (WT) littermates were subjected to 75%
oxygen from postnatal day 7 (P7) to P12 and then returned to room air. At P17 retinal
vascularization was examined from whole mounts, and retinal vascular permeability was
studied using Miles assay. Real-time RT-PCR, Western blotting, and immunohistochemistry
were used to assess the expression of R-Ras in retina during development or in the OIR
model. The degree of pericyte coverage and vascular endothelial (VE)-cadherin expression on
WT and R-Ras KO retinal blood vessels was quantified using confocal microscopy. The
correlation of R-Ras with vascular endothelial growth factor receptor 2 (VEGFR2) and human
serum albumin on human proliferative diabetic retinopathy membranes was assessed using
immunohistochemistry.
RESULTS. In retina, R-Ras expression was mostly restricted to the vasculature. Retinal vessels in
the R-Ras KO mice were significantly more permeable than WT controls in the OIR model. A
significant reduction in the direct physical contact between pericytes and blood vessel
endothelium as well as reduced VE-cadherin immunostaining was found in R-Ras–deficient
mice. In human proliferative diabetic retinopathy neovascular membranes, R-Ras expression
negatively correlated with increased vascular leakage and expression of VEGFR2, a marker of
blood vessel immaturity.
CONCLUSIONS. Our results suggest that R-Ras has a role in controlling retinal vessel maturation
and stabilization in ischemic retinopathy and provides a potential target for pharmacologic
manipulation to treat diabetic retinopathy.
Keywords: retina, diabetic retinopathy, neovascularization, retinal ischemia
iabetic macular edema (DME) and proliferative diabetic
retinopathy (PDR) are the two forms of diabetic retinop- athy
causing  blindness.  Vascular  endothelial  growth  factor
(VEGF) plays a crucial role in these diseases by causing vascular
leakage and pathologic neovascularization.1–3 Anti-VEGF drugs
are regarded as the mainstay of treatment for patients affected
by DME. However, VEGF inhibition fails to provide sufficient
efficacy in all DME cases; only half of patients attain significant
improvement  in  visual  acuity.4 Anti-VEGF  therapy  is  also
accompanied  by  rare,  but  severe,  ocular  and  systemic  side
effects. In PDR, anti-VEGF may be associated with development
of  tractional  retinal  detachment5,6 Furthermore,  intravitreally
administered anti-VEGF agents may cause sustained systemic
VEGF inhibition7,8 This is why they are relatively contraindi-
cated  in  pregnant  women9 and  patients  with  cardiovascular
insufficiency.10,11 Thus, alternative therapies are needed for
more effective and safer treatment of diabetic retinopathy.12,13
R-Ras is a small GTPase of the Ras family of oncogenes.14
Despite the close structural similarity to other members of the
Ras family, the function of R-Ras is distinct from other Ras
proteins.15 Whereas all other members of the Ras family may
cause malignant transformation, R-Ras has very little or no
transforming activity.16 Furthermore, the opposing functions of
R-Ras and H-Ras extend to cell–extracellular matrix (ECM)
adhesion,17 cell differentiation,18 and signaling.19 These oppos-
ing functions have led to the suggestion that the balance
between R-Ras and other Ras members acts as a switch that
controls  proliferation  and  invasion  versus  quiescence  in
cells.15,20,21
Recently, active Ras signaling has been implicated as a key
driver of pathologic angiogenesis in neovascular diseases of the
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retina.22 Conversely, exactly the opposite role  has  recently
been shown for R-Ras in the regulation of angiogenesis.20 R-Ras
function has been shown to be essential for the establishment
of mature and functional blood vessels in tumors by
stabilization of immature, leaky vessels, enhancing perfusion
and ultimately reducing plasma leakage.15,21 Based on these
functions, R-Ras has been classified as an antiangiogenic
molecule. However, R-Ras is functionally different from classic
antiangiogenic agents as it does not induce endothelial cell
apoptosis as do other antiangiogenic molecules, but actually
promotes endothelial cell survival.20 Thus, R-Ras could provide
a potential agonistic therapeutic target for treatment of a
variety of retinal diseases associated with ischemia, neovascu-
larization, and vascular leakage. In the present study, the role of
R-Ras in the retina was studied by analyzing expression of R-Ras
in the retina and by analyzing the effect of R-Ras deficiency on
the structural and functional integrity of retinal vasculature
during development and ischemic retinopathy using an
oxygen-induced retinopathy model (OIR). To address the role
of R-Ras in PDR, association of its expression with vascular
immaturity and leakiness was examined in human retinal
neovascular membranes.
METHODS
Mice
For the experiments, wild-type (WT) C57BL/6 mice from
Harlan Sprague Dawley (Indianapolis, IN, USA) and homozy-
gous R-Ras knockout (KO) mice were used. R-Ras KO mice
with an insertion deleting R-Ras expression between exons 4
and 5 of Rras	 on chromosome 7 (R-Ras KO mice) have been
described previously.20 Before any experiments, R-Ras hetero-
zygous mice were backcrossed eight times with the C57BL/6
strain to obtain homozygous KO and WT mice in the same
genetic background. The mice were bred, and the genotype
was determined by PCR. Mice were fed with standard
laboratory pellets and water ad libitum. All animal experiments
were performed according to the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research in accordance
with protocols approved by the National Animal Ethics
Committee of Finland.
Oxygen-Induced Retinopathy Model
The experiments on the OIR model were carried out as
described in detail previously.23,24 Briefly, neonatal mice at
postnatal day 7 (P7) were exposed to 75% oxygen for 5 days. At
P12, they were returned to normal room air.23 Animals were
euthanized at P12 to assess the degree of vascular regression
and at P17 to determine the rate of retinal revascularization
and preretinal neovascularization. As postnatal weight gain has
been shown to affect outcome in the OIR model,25 only the
pups weighing between 6.3 and 7.5 g at P17 were included in
the study.
Immunohistochemistry (IHC) and Isolectin GS-IB4
Staining
For the analysis of retinal vasculature, eyes were enucleated,
fixed with 4% paraformaldehyde (PFA), and retinas dissected.
Flat-mount retinas were blocked in 20% normal goat and 20%
fetal bovine serums for 2 hours, incubated overnight Isolectin
(Isolectin GS-IB4, 1:200; Invitrogen, Carlsbad, CA, USA) and
with anti-NG2 chondroitin sulfate proteoglycan antibody (1:80;
Millipore, Billerica, MA), followed by Alexa Fluor-conjugated
secondary antibody. Retinas were imaged via confocal micro-
scope (LSM 700; Carl Zeiss, Oberkochen, Germany) and the
rate of angiogenesis was determined during development (P0–
P6) and in the OIR model as previously described.24 Briefly,
retinas were imaged using confocal microscopy (Carl Zeiss LSM
700) with 53 objective. By focusing just above the inner
limiting membrane of the retina, the preretinal neovascular
tufts were readily distinguished from the underlying superficial
vascular plexus. Areas of vascular obliteration and pathologic
neovascularization (meaning neovascular tufts) were quanti-
fied from these images using image editing software (Adobe
Photoshop CS3; Adobe Systems, Inc., San Jose, CA, USA). The
rate of developmental angiogenesis at P0 to P6 was determined
by measuring the length of vasculature from the optic nerve to
the tips of the blood vessels. Four measurements per retina
were taken and an average was calculated.
For immunohistochemistry, the eyes were fixed with 4%
PFA and embedded in paraffin or immediately frozen in
ornithine carbamoyltransferase embedding compound in iso-
pentane cooled with liquid nitrogen and later fixed with
acetone. The IHC was carried out on 4- to 6-lm-thick tissue
sections using the following primary antibodies: rabbit anti–R-
Ras (1:50) and rabbit anti-VEGFR2 (1:100; both Cell Signaling
Technology, Danvers, MA, USA), rabbit anti–R-Ras (1:750) and
mouse anti-VEGFR2 (1:200, clone sc.6251; both Santa Cruz
Biotechnology, Dallas, TX, USA), rat anti-mouse CD31 (1:50;
BD Pharmingen, San Diego, CA, USA), guinea pig anti-NG2
antibody (1:100, gift from William Stallcup),26 rabbit anti-
Syndecan (1:500) and rabbit anti-human vascular endothelial
(VE)-cadherin (1:500; both from Abcam, Cambridge, UK), and
rabbit anti-human serum albumin (1:100; Lifespan Biosciences,
Seattle, WA, USA), followed by horseradish peroxidase (HRP)
or fluorescein-conjugated secondary antibodies. Hematoxylin
staining was used as a counterstain. Samples were mounted
with Vectashield mounting medium with 40,6-diamidino-2-
phenylindole (Vector Laboratories) and analyzed via confocal
microscope. Each staining experiment included sections
stained without primary antibody as negative controls.
Percentage of R-Ras positive cells in preretinal  neovessels
were quantified manually by using the count tool in Adobe
Photoshop (Adobe Systems, Inc.) (n	¼ 6 mice, 4–6 sections/
retina).
Quantification of Pericyte Coverage and VE-
Cadherin Colocalization With CD31
Pericyte coverage of the blood vessels was quantified from WT
and R-Ras KO P17 OIR model whole-mount retinas. Samples
were imaged using confocal microscopy (Carl Zeiss LSM 700)
with a 633 objective lens, and 3D pictures were made from Z-
stacks. Pictures selected for the analysis were randomly taken
from Isolectin IB4 and NG2-stained flat-mounts from the most
superficial vascular plexus at the tips of the blood vessels next
to avascular area. This is a region of retina where the blood
vessels are growing toward the optic nerve. Direct contact
between pericytes (NG2) and endothelial cells (Isolectin B4)
were quantified by colocalization analysis with BioImageXD
(provided in the public domain at http://www.bioimagexd.
org).27 The percentage of EC area colocalized with pericyte
area was quantified in each image, and the result expressed as a
mean of two different images for each retina. The intensity of
VE-cadherin staining and colocalization of VE-cadherin and
CD31 was quantified from frozen sections using BioImage XD.
Real-Time Quantitative PCR (qPCR)
Eyes were collected at P0, P4, P7, P12, P17,  and  P22  and
placed immediately in cold RNA stabilization reagent (RNA-
later;  Sigma-Aldrich  Corp.,  St.  Louis,  MO,  USA)  for  the
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duration of dissection of the retinas. RNA was extracted using
RNA isolation kit (RNeasy Mini Kit; Qiagen, Hilden, Germany)
following the manufacturer’s instructions. The integrity of
extracted RNA was verified  on formaldehyde agarose gel.
Reverse transcription of RNA was carried out using cDNA
synthesis kit (Maxima First Strand cDNA Synthesis Kit;
Thermo Fisher Scientific, Boston, MA, USA), according to
the manufacturer’s instructions. Real-time qPCR was done
using the PCR dye (SYBR Green; Thermo Fisher Scientific)
method according to the manufacturer’s recommendations
and performed in white 96-well plates (Multiply PCR plates;
Sarstedt, Nu¨mbrecht, Germany). The fluorescence signal was
detected using a sequence detection system (ABI Prism 7000
Sequence Detection System 1.2; Applied Biosystems, Carls-
bad, CA, USA). The following intron-spanning primers
specific for exon 3 and 4 of Rras	were used: 50-ACAGGCA
GAGTTTCAATGAG-30 (forward),  50-GTTCTCCAGATCTGCC
TTG-30 (reverse). Ppia	 was used  as  an  endogenous  control
gene  (50-CACCGTGTTCTTCGACATC-30 and  50-ATTCTGTGA
AAGGAGGAACC-30), allowing the comparison of samples.20
Two or three replicates were analyzed for each sample, and
the  results  were  expressed  as  a  mean  for  each  sample.
Negative, no template (NTC) and no reverse transcriptase (no
RT), controls were included in every qPCR analysis. A melting
curve analysis was performed to check for unspecific PCR
products (which didn’t occur). Reaction efficiencies for both
primer pairs were tested with standard curve analysis in
different time points. Due to similar efficiencies for both
primer pairs, the differences in gene expression levels were
determined by the comparative Ct method (DDCt method).28
Vascular Permeability Assay
Vascular permeability was quantified by Miles assay in retinas
as described previously.29 Briefly, the mice were injected with
2% Evans Blue ([EB], 150 lL/20g; Sigma-Aldrich Corp.)
intraperitoneally, and the circulation time was 24 h for P16
or 1 hour for P17 injected mice. Phosphate-buffered saline–
injected mice were used as a negative control. Animals were
euthanized at P17, and blood was collected from the left
ventricle. Retinas were dissected and weighed. Blood was
centrifuged at 3,550g	 for 15 minutes, and plasma was diluted
1:100 and 1:1000 in N, N-dimethylformamide (Sigma-Aldrich
Corp.). All samples were incubated in a shaker (100 rpm) in
200 lL N, N-dimethylformamide overnight at 788C. Retinas
were centrifuged at 17,000g	 for 45 minutes at 48C, and the
supernatants were collected. The EB absorbance of each
sample was measured at 620 nm by spectrophotometer. EB
concentration in the retina was proportioned and normalized
by the weight of the retina and the amount of EB concentration
in the plasma.30
Western Blotting
Retinas were lysed in 10 lL of cold RIPA buffer per 1 mg of
tissue with added protease inhibitor (cOmplete; Roche, Basel,
Switzerland) and phosphatase inhibitor (Halt; Thermo Fisher
Scientific).
The tissues were homogenized using CK14 beads and a
tissue homogenizer (Precellys; Bertin Technologies, Montigny le-
Bretonneux, France). From each sample, 40 lg of protein was
loaded per well of a 4-12% gradient gel (NuPAGE; Invitrogen,
Carlsbad, CA, USA) and electroblotted on polyvinylidene
fluoride membranes (Immun-Blo; Bio-Rad Laboratories, Hercu-
les, California). For detection of specific proteins by immuno-
blotting, the following primary antibodies were used: rabbit
anti–R-Ras (1:500; Cell Signaling Technology), goat anti-GAPDH
(1:500:  AbCam)  and  horse  anti-mouse  IgG  (1:2000;  Cell
Signaling Technology). Primary antibodies were detected by
HRP-coupled antibodies. Western blot images were captured via
software (ImageQuant; GE Healthcare, Chalfont St. Giles, UK)
and quantified by densitometry using Adobe Photoshop CS3
software, where GAPDH was used to normalize for protein
loading. A calibrator control sample was included in every
membrane to enable sample comparison between different
membranes.
Retinal and Neovascular Samples From Human
Patients
Preretinal neovascular membranes were obtained from eight
type I diabetic patients who were undergoing pars plana
vitrectomy for the treatment of PDR. All patients were
Caucasians, and altogether there were five females and three
males. At the time of pars plana, vitrectomy patients’ mean
age was 33 years (range, 27–56 years) and mean duration of
diabetes was 24 years (range, 16–32 years). Normal human
retinas were obtained from patients whose eyes were
enucleated due to choroidal melanoma. The protocol for
collecting human tissue samples was approved by the
institutional review boards of the Pirkanmaa Hospital
District and the Kuopio University Hospital. The study was
conducted in accordance with the Declaration of Helsinki.
All patients gave written informed consent. During vitrecto-
my, the fibrovascular membranes were  isolated,  grasped
with vitreous forceps, and pulled out through a sclerotomy.
The sample was immediately fixed with 4% formaldehyde for
3 h, transferred to 70% ethanol, embedded in paraffin, and
processed for immunohistochemistry. The number of R-Ras–
positive neovessels was calculated from CD31 and R-Ras–
double-stained tissue sections, and correlation between R-
Ras and VEGFR2 was quantified from R-Ras and VEGFR2
double-stained sections. Immunohistochemistry against hu-
man serum albumin (HSA) was done to quantify the amount
of vascular leakage outside the neovessels. Quantification
was done using IHC Profiler plugin in ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by
National Institutes of Health, Bethesda, MD, USA). The area
of positive staining for HSA was compared to the total
analyzed area, and correlation analysis between HSA and
percentage of R-Ras–positive neovessels was performed for
each sample.
Statistical Analysis
Student’s t-test was conducted for normally distributed data
and nonparametric Mann-Whitney U	 test using statistical
software (GraphPad Prism 6.01; GraphPad Software, San
Diego, CA, USA, and IBM SPSS Statistics; IBM, Amonk, NY,
USA) for nonnormally distributed data to test the statistical
significance of the results. Spearman’s rank correlation test was
conducted to test correlation between two variables. P	 values
less than 0.05 were considered statistically significant.
RESULTS
R-Ras Expression Peaks During Retinal
Developmental Angiogenesis But Does Not
Influence the Rate of Developmental Angiogenesis
R-Ras KO mice are fertile and show no obvious morphologic
abnormalities,20,31 and their eyes appear normal upon histo-
logic examination. To address the role of R-Ras on retinal
angiogenesis in vivo, the expression profile of R-Ras in the
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FIGURE 1. Hypoxia-driven R-Ras expression in the OIR model. Hypoxia-induced angiogenesis in retina was studied with the OIR model. Retinas
were harvested immediately after the exposure to hyperoxia (P12) and after hypoxia-driven pathologic angiogenesis has reached its maximum at
P17. Retinas from normal mice were harvested at corresponding time points. Retinas were subjected to either quantitative mRNA (real-time qPCR)
analysis using SYBR Green method or protein (Western blotting) analysis. For immunoblotting, retinal protein supernatants were electrophoresed
on gradient gels, standard Western blotting was carried out with R-Ras–specific antibody, and GAPDH detection was used as a loading control. (A)
The graph represents fold changes (2-DDCt method) in the Rras	mRNA expression level relative to the Rras	 mRNA expression level of normal mice at
P12. The level of Rras	mRNA  expression between  normal  and OIR model retinas is equal  at P12,  whereas at P17 hypoxia  leads  to  2.5-fold
upregulation of Rras	mRNA (P	 ¼ 0.016, * nonparametric Mann-Whitney U	 test). Error	bars	 represent the minimum and maximum of the fold
change. (P12, P17 OIR: n	¼ 4;  P17,  P12  OIR: n	¼ 5.) (B, C) The level of R-Ras protein expression was quantified by densitometric analysis of
immunoblotted protein. R-Ras protein level at P17 shows a 7.5-fold increase (P	¼ 0.016) during hypoxia-induced angiogenesis. Error	 bars	 represent
6 95% confidence intervals. (P12: n	¼ 6; P12 OIR: n	¼ 7; P17: n	¼ 5; P17: n	¼ 5.) The results are analyzed with nonparametric Mann-Whitney U	 test.
The samples presented above were run on the same gel. Representative samples were cropped and presented side-by-side.
developing mouse retina as well as the developmental rate of
angiogenesis in WT and R-Ras KO mice were characterized.
To assess the temporal expression pattern of R-Ras during
developmental retinal angiogenesis, qPCR and Western blot
analysis were used. Quantitative PCR demonstrated that the
Rras	mRNA expression increased from P0 onward, peaked at
P17, and started to decline from P17 until P22. Western blot
analysis demonstrated a R-Ras protein expression profile
similar to the mRNA profile: an increase in expression from
P0 until P17 and a decline from P17 to P22 (Supplementary
Fig. S1). The increase in Rras	mRNA and protein levels from
P0 to P17 correlates with the development of retinal
vascular plexuses.32 The R-Ras levels peaked at P17, when
all three vascular plexuses are formed and vascular density
peaks  in  the  retina33 (Supplementary Fig. S1). The findings
are consistent with the notion that R-Ras appears  in  the
blood vessels during their differentiation and is most
strongly expressed  in  fully  differentiated,  quiescent  blood
vessels.20 The reduction in Rras	 mRNA and protein
expression levels from P17 to P22 can be explained by the
remodeling of retinal vasculature (including vascular prun-
ing), the outcome of which is decreased endothelial cell
density at P28.34 Consistent with this  finding,  the  results
show  a  similar  decrease  in  the  intensity  of  Isolectin  IB4
staining from P12 onward (Supplementary Fig. S2). No R-Ras
protein or mRNA expression was detected in the retinas
collected from R-Ras KO mice.
To explore whether the increase in R-Ras expression level
seen during retinal development influences the rate of
superficial vascular plexus formation  (developmental  angio-
genesis), retinas from P0, P2, P4, and P6 WT and R-Ras KO
mice were analyzed. In P0, P2, P4, and P6 neonatal mice, the
diameter of retinal superficial vascular plexuses were similar
both  in  R-Ras  KO  and  WT  mice,  indicating  that  R-Ras
expression is not necessary for in vivo angiogenesis during
neonatal development (Supplementary Fig. S3). The lack of
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FIGURE 2. R-Ras is strongly, but selectively expressed in the endothelial cells and pericytes of blood vessels in retina. Oxygen-induced retinopathy
was induced by exposing WT pups to 75% oxygen at P7 for 5 days and returning them to normal room air at P12. After 5 days in normoxia (at P17),
the R-Ras expression was determined from the revascularized retinas by IHC and immunofluorescence (IF) using R-Ras–specific primary antibody.
(A) Representative images of R-Ras expression in the OIR model. More than 30% of the preretinal blood vessels are negative for R-Ras (arrow),
whereas blood vessels in retina are R-Ras positive (arrowhead). Right, negative control (no primary antibody). There is also faint R-Ras expression
from other retinal cells, presumably from neural cells in the retina. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer, OPL,
outer plexiform layer; ONL, outer nuclear layer; IS/OS, photoreceptor inner/outer segments; RPE, retinal pigment epithelium. (B–E) Representative
confocal images showing the colocalization of R-Ras (green) and CD31 (red) in the retina of frozen sections after immunofluorescence staining. (C)
R-Ras is expressed in the endothelial cells in the retina and (D) also in the preretinal blood vessels. (E) Some of the preretinal blood vessels are
negative for R-Ras. (F) R-Ras is expressed in the pericytes (NG2, red) in the retina. Some pericytes of preretinal blood vessels are negative for R-Ras
in OIR (arrow), but (G) R-Ras is also expressed in the pericytes of preretinal neovessels. Scale	bars: 100 lm (A, B), 20 lm (C–G).
influence on development of retinal vasculature by R-Ras is in
line with the above-reported low expression of R-Ras at the
early stages of retinal vascular development (Supplementary
Fig. S1).
Induction and Selective Disappearance of R-Ras
From the Pathologic Neovasculature in OIR
Next, the R-Ras expression profile in the OIR model was
analyzed using WT mice. Using qPCR, a 2.5-fold increase of
Rras	mRNA from normal P17 to P17 OIR model retinas was
detected. Using Western blot analysis, a 7.5-fold increase in R-
Ras protein levels was seen in OIR P17 retinas compared to
healthy P17 retinas. At P12, the expression of R-Ras was
reduced in OIR. The amount of R-Ras expression is in line with
regression of the vasculature at P12 and vessel regrowth at P17
in the OIR model (Fig. 1). Using R-Ras immunohistochemistry,
R-Ras was found to be localized mainly to the blood vessels in
OIR retinas (Fig. 2, Supplementary Fig. S4). A faint R-Ras
expression was also detected outside of the retinal blood
vessels in mouse retina (Fig. 2A). This immunohistochemical
signal most probably represents low expressions from retinal
neuronal cells, which are known to express R-Ras.35 Using R-
Ras and endothelial cell (CD31), as well as R-Ras and pericyte
(NG2), double-staining, R-Ras expression was shown to be
confined to endothelial cells and pericytes in retinal vessels
(Fig. 2). It appeared that all of the retinal blood vessels
expressed R-Ras, whereas only 68% of the preretinal neovessels
had R-Ras  expression at  P17 in the OIR  model (Fig. 2A,
Supplementary Fig. S4). This finding was confirmed by double
immunofluorescent imaging of the retina showing some
preretinal neovessels devoid of R-Ras expression in OIR (Figs.
2E, 2F). By costaining the retinal tissue sections for R-Ras and
endothelial cells, as well as for R-Ras and pericytes, the R-Ras
expression was confirmed to be confined to both endothelial
cells and pericytes (Figs. 2B–G).
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FIGURE 3. Neither revascularization nor pathologic neovascularization is affected by R-Ras deficiency in the OIR model. Wild-type and R-Ras KO
mice pups were exposed to hyperoxia as previously described, and retinas were harvested at P17. Areas of vascular obliteration and pathologic
neovascularization (meaning neovascular tufts) were quantified from Isolectin IB4–stained whole mounts using Adobe Photoshop CS3. (A)
Representative retinas of WT and R-Ras KO mice at P17. The revascularization rate was determined by quantifying the avascular areas ( yellow) in
retinal flat mounts. The amount of pathologic neovascularization (tufts, red) was also determined. (B) Summary of quantitative analysis of vascular
obliteration (yellow) and neovascularization (red). The avascular and pathologic neovascularization areas were measured, and results  are
represented as an area relative to WT area. Error	bars	 represent 6 95% confidence intervals. (WT: n	¼ 63, KO: n	¼ 48 retinas.)
R-Ras Does Not Change the Hypoxic
Revascularization Rate of the Retina
As all of the antiangiogenic molecules used to treat neovascular
retinal diseases have been shown to inhibit sprouting
angiogenesis induced in the OIR model,36–38 the role of R-Ras
in hypoxia-driven neovascularization in the retina was ex-
plored next. First, we determined whether regression of
vessels under hyperoxic conditions in the OIR model is
comparable between R-Ras KO and WT mice. After exposure
to 75% oxygen between P7 and P12, retinas were evaluated at
P12. Typical for this model,39 large areas of the central vascular
network were obliterated, with only a few major vessels
remaining centrally in both WT and R-Ras KO mice
(Supplementary Fig. S5). Quantitative analysis of obliterated
areas in retina confirmed that the retinal vasculature in R-Ras
KO and WT mice are affected in a similar fashion by hyperoxic
exposure (Supplementary Fig. S5). Taken together, these data
suggest that deletion of R-Ras has no observable effect on
vascular regression and remodeling in the retina in response to
hyperoxic  conditions.
On return to normoxia, the avascular and hypoxic central
retina stimulates rapid regrowth of vessels.24 The rate of retinal
revascularization in WT and R-Ras KO retinas was determined
by quantifying avascular retinal area 5 days after the mice were
returned to normoxia. There was no significant difference in
the avascular retinal area between the WT and R-Ras KO,
indicating that the rate of retinal revascularization is similar
between the WT and R-Ras KO mice at P17 (Fig. 3). In addition
to revascularization of the retina, the strong hypoxic stimulus
from the center of the retina also drives abnormal misdirected
sprouting of blood vessels into the vitreous at the interface
between the centrally obliterated and peripherally perfused
retina.24 Preretinal (i.e., pathologic) neovascularization reaches
its maximum in WT mice 5 days after returning to normoxia (at
P17).24 No significant differences in the number of preretinal
neovascular tufts and clusters were found between R-Ras KO
mice and WT mice (Fig. 3). The results indicate that neither the
hypoxia-induced revascularization rate of the obliterated areas
in retina nor the rate of preretinal neovascularization is
affected by R-Ras deletion.
R-Ras Deficient Retinal Blood Vessels Have
Increased Permeability in OIR
It has been recently shown that loss of R-Ras worsens blood
vessel structure and perfusion and the pathologic plasma
leakage in tumor angiogenesis.15,21 In order to assess the role
of R-Ras in controlling the vascular permeability of the retinal
vasculature, the OIR model was used. The vascular leakage was
quantified by measuring EB dye extravasation from retinal
vessels. The R-Ras KO retinas had approximately 100% increase
in the retinal EB leakage compared with the WT retinas in OIR
(P	¼ 0.0223 at 1 hour and P	¼ 0.0006 at 24 hours; Figs. 4A–C).
No difference was detected in the amount of EB leakage when
comparing normal WT and R-Ras KO retinas (Supplementary
Fig. S6). To confirm the enhanced retinal leakage in R-Ras KO
animals in OIR, we also measured the amount of IgG heavy
chain molecule accumulation in the retina, as this antibody
subclass is normally compartmentalized within the circula-
tion.40 We could not detect a difference in IgG leakage in the
normal retinas between WT and R-Ras KO animals. A 4-fold
increase in the amount of IgG was detected in the R-Ras KO
retinas over the WT retinas in OIR as a sign of increased
vascular permeability (P	¼ 0.0007; Fig. 4D). To rule out the
possibility that the increased levels of IgG in the R-Ras KO OIR
retinas were due to plasma cells, immunohistologic staining of
CD138/Syndecan-1 was performed. There was no increase in
the number of plasma cells in KO retinas compared to WT in
the OIR samples (Supplementary Fig. S7).
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FIGURE 4. R-Ras deficiency increases vessel permeability in mouse OIR
model. Wild-type and R-Ras KO mice pups were exposed to hyperoxia
as described previously. The EB dye was injected IP, and retinas and
blood samples were harvested after 1 hour and 24 hours at P17. Evans
Blue concentrations were measured spectrophotometrically at 620 nm,
and EB concentration for each sample was calculated from a standard
curve. Results are expressed as relative to EB concentration in the
plasma. (A) Representative R-Ras KO and WT OIR retinas after systemic
injection of EB dye. In many of the R-Ras KO retinas, EB dye was visible,
whereas most of the WT retinas were colorless. (B) Statistical analysis
of a representative experiment shows a significant increase in vascular
leakage in R-Ras KO OIR retinas compared to WT OIR retinas already at
a 1-hour time point (P	¼ 0.0223, *, nonparametric Mann-Whitney U	
test, WT n	¼ 6,  R-Ras  KO n	¼ 8).  (C) There is a highly significant
difference in vascular leakage between R-Ras KO and WT mice at the
24-hour time point (P	¼ 0.0006, ***, nonparametric Mann-Whitney U	
test; WT n	¼20, R-Ras KO n	¼18). Error	bars	represent SEM. To assess
the IgG protein accumulation, OIR retinas were harvested at P17,
proteins were extracted and samples were electrophoresed on gradient
gels, and Western blotting was done using anti-mouse IgG antibody. (D)
Representative images of immunoblotting from where mouse  IgG
heavy chain densities were quantified and normalized against GAPDH.
Relative comparison of IgG heavy chain protein from WT OIR and R-
Ras KO OIR samples gives a 3.5-fold difference (P	¼ 0,0007, ***,
nonparametric Mann-Whitney U	 test). There is no difference in the IgG
protein level between healthy WT and KO mice at P17 (P	¼ 0.7879).
Error	bars	represent 6 95% confidence intervals. (WT: n	¼ 6, KO: n	¼
6, WT OIR: n	¼14, KO OIR: n	¼ 16.)
R-Ras Deficiency Severely Impairs Pericyte
Coverage of Angiogenic Blood Vessels and Reduces
VE-Cadherin Expression in OIR Model
Close interaction between sprouting endothelium and peri-
cytes is crucial for vessel maturation and stability.41,42
Pathologic, angiogenic  vasculature  in  tumors  is  characterized
by insufficient pericyte association around the blood vessels.43
Consistent with this notion, a significant reduction in  the
direct physical contact between pericytes and the endothelium
of blood vessels was found in R-Ras KO retinas in the OIR
model at P17 (Figs. 5A–B). When the pericyte coverage around
the tips of the sprouting angiogenic  blood  vessels  was
quantified, 40% reduction in  the  pericyte  coverage  was
recorded in the R-Ras KO retinas over the WT retinas (P	 ¼
0.033; Fig. 5C).
Vascular endothelial–cadherin is a member of cadherin
superfamily expressed exclusively on endothelial cells.21 It is a
crucial factor of adherens junctions between the endothelial
cells.15 R-Ras is known to stabilize adherens junctions by
inhibiting  VEGF-induced  VE-cadherin  internalization.15 We
studied the expression of VE-cadherin in OIR model, and we
observed that both the intensity of the VE-cadherin immuno-
staining and colocalization of VE-cadherin with CD31 were
significantly reduced in KO mice compared to WT mice (Fig.
5D). Colocalization analysis showed significant reduction in
VE-cadherin and CD31 colocalization in R-Ras KO mice
compared to WT mice (overlap coefficient according to
Manders: r	¼ 0.51 for WT, and R	¼ 0.43 for KO (P	¼ 0.04)).
Our finding on VE-cadherin expression is in line what has been
reported in tumor vasculature of R-Ras KO and WT mice.21
Reduced R–Ras Expression in the Neovessels of
Human Diabetic Retinopathy Correlates With
Increased Vascular Leakage and the Immature State
of the Neovessels
R-Ras expression was restricted exclusively to blood vessels in
normal human retina, and it was expressed in all blood vessels
in normal human retinas (Supplementary Fig. S8). To address
the relevance of our findings on the role of R-Ras in the OIR
model to human ischemic retinopathies, the pathologic retinal
neovascular membranes that develop in human diabetic
retinopathy patients were studied. These neovascular mem-
branes  were  collected  from  patients  suffering  from  type  I
diabetes, who had already developed tractional retinal detach-
ment due to  fibrosis of neovascular membranes. Thus, the
samples represent the end stage of the disease, where
substantial amount of fibrosis is associated with neovessels,
but they still contain regions with active pathologic angiogen-
esis. In the diabetic neovascular membranes, R-Ras expression
was exclusively restricted to blood vessels (Fig. 6). Like
pathologic preretinal neovessels in the OIR model, human
diabetic neovascular membranes had varying expression of R-
Ras (Fig. 6). Only approximately 80% of the blood vessels in the
human neovascular membranes expressed any R-Ras protein at
all (Fig. 6C). To explore whether R-Ras expression has any
relation to the blood vessel maturity, the human tissue samples
were double-stained for R-Ras and VEGFR2, a marker of blood
vessel immaturity.44,45 A strong inverse correlation between
expression of the two proteins was identified (Spearman’s q ¼
-0.821, P	¼ 0.023, R2 ¼ 0.563); the higher the percentage of
immature blood vessels (VEGFR2þ), the less R-Ras expression
there was in the blood vessels (Fig. 6).
To address whether lack of R-Ras in immature blood vessels
influences vascular permeability  in  human  diabetic  neovascu-
lar membranes, samples were stained for HSA. Samples with a
low percentage of R-Ras–expressing blood vessels showed a
strong accumulation of HSA outside the vessels, whereas
samples with a high percentage of R-Ras–expressing blood
vessels had HSA staining  restricted mainly inside the vessels
(Figs. 6A–B). There was a strong negative correlation between
area of extravascular HSA and the number of R-Ras–positive
vessels (Spearman’s q: r	¼ -0.886, P	¼ 0.019, R2 ¼ 0.835); the
more vascular leakage outside of the blood vessels, the less R-
Ras expression was in the blood vessels.  Furthermore,  we
could demonstrate that leaked, extravascular HSA was detected
mainly around individual blood vessels that lack R-Ras (Fig. 7).
This was especially evident in samples that had R-Ras in the
majority of blood vessels as extravascular HSA mainly
accumulated around those few blood vessels devoid of R-Ras
expression (Fig.  7).
DISCUSSION
The present study demonstrates that the small GTPase R-Ras
regulates the pathologic permeability of blood vessels in
hypoxia-driven  angiogenesis  without  altering  the  rate  of
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FIGURE 5. Pericyte coverage and VE-cadherin expression is reduced in R-Ras KO in the OIR model in angiogenic retinal blood vessels. Oxygen-
induced retinopathy was induced in WT and R-Ras KO mice as described previously. Retinas were harvested at P17, and whole-mount retinas were
double-stained with Alexa Fluor–conjugated Isolectin IB4 and with an antibody against the pericyte marker NG2 proteoglycan. Three-dimensional
images were taken from the most superficial vascular plexus at the tips of the blood vessels from the region where vessels grow toward the optic
nerve. (A) Representative images of WT and R-Ras KO blood vessel endothelial cells (red) surrounded by pericytes (green). (B) The majority of
images from WT mice retina had a lot of pericytes around the blood vessels, whereas the majority of pictures taken from the KO retinal blood
vessels were lacking or had very few pericytes. (C) Direct contact between endothelial cells and pericytes was quantified by colocalization analysis.
The result is shown as a percentage of endothelial cell area colocalized with pericytes in WT and R-Ras KO retinal blood vessel tips. The pericyte
coverage is significantly reduced in R-Ras KO animals compared to WT by 40% (P	¼ 0.033, *). Error	bars	represent 6 95% confidence intervals.
(WT: n	¼ 15; R-Ras KO: n	¼ 15. Two pictures were taken from each retina, and an average was calculated). The expression of VE-cadherin was
studied in the OIR model by staining frozen cross-sections of retina with antibodies against VE-cadherin and endothelial cells (CD31). The intensity
as well as the colocalization of VE-cadherin staining with endothelial cells was quantified using BioImageXD. (D) Representative images of VE-
cadherin (green) and CD31 (red) in P17 OIR model in WT and R-Ras KO are presented. Colocalization analysis showed significant reduction in VE-
cadherin and CD31 colocalization in R-Ras KO mice compared to WT mice (overlap coefficient according to Manders: r	¼ 0.51 for WT and R	¼ 0.43
for KO [P	¼ 0.04]), n	¼ 5 mice for WT and n	¼ 5 mice for KO.
revascularization of the hypoxic retina. Furthermore, by
analyzing a set of preretinal vascular membranes  obtained
from diabetic retinopathy patients, we were able to demon-
strate that neovascular membranes with reduced R-Ras
expression in immature vessels display increased pathologic
vascular leakage. Given that increased vascular leakage is the
pathognomonic feature in human diabetic retinopathy, our
study implicates that loss of R-Ras may have a pathologic role in
this disease.
R-Ras reduced the pathologic vascular permeability in
ischemia-induced retinopathy without inhibiting retinal angio-
genesis, whether it was developmental or induced by hypoxia
in OIR. This is a clear difference to all current available
antiangiogenic therapies that have been shown to function in
OIR by inhibiting sprouting angiogenesis.36 Furthermore, the
mechanism of resistance to the currently available antiangio-
genic therapies both in tumors and retinopathy is actually
related to the eradication of the neovessels, which, in turn,
worsens the underlying ischemia and drives the formation of
new, leaky blood vessels by alternative molecular mecha-
nism.13 Thus, the proposed molecular mechanism for future
antiangiogenic therapies is one in which the angiogenic blood
vessels are ‘‘normalized’’ to stable ones to alleviate the hypoxia
and stop the detrimental aberrant vascular leakage.46,47 Taken
with earlier demonstrations of a causal relationship between R-
Ras expression and vessel maturation,15,20,48,49 our results
suggest potential utility of R-Ras in treating retinopathies
involving angiogenesis. Modulating R-Ras expression repre-
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FIGURE 6. Reduced R-Ras expression correlates with leakage of human serum albumin in human diabetic retinopathy vasculature, and it is
negatively correlated with VEGFR2 expression. Preretinal neovascular membranes obtained from vitrectomies from diabetic retinopathy patients
were analyzed by immunohistochemistry for their protein expression. Immunohistochemical staining from adjacent sections was done with anti-
CD31þanti–R-Ras, anti-HSA, and anti–R-Rasþanti-VEGFR2 antibodies. The number of R-Ras–positive vessels was calculated from R-Ras and CD31
double-stained sections (n	¼7; 5–9 different sections analyzed from each sample). Correlation analysis between R-Ras and VEGFR2 was done from R-
Ras þ VEGFR2 double-stained sections and compared to CD31 staining from adjacent sections (n	¼ 7; 5–9 different sections analyzed from each
sample). Vascular membranes with strong R-Ras expression show limited extravascular staining for HSA (A), whereas samples with weak R-Ras
expression show strong staining for HSA outside the blood vessels (B). Scale	 bars: 100 lm. There is a strong inverse correlation between HSA-
positive extravascular area and the percentage of R-Ras–positive neovessels (Spearman’s q: r	¼-0.886, P	¼0.019, *, R2 ¼0.835, n	¼6 patients) (D).
(C) Approximately 20% of the neovessels do not express any R-Ras at all (R-Ras–positive vessels 81 6 10%, mean þ SD, n	¼ 6 patients). Data are
shown as a box plot with median and 95% confidence interval. (E, F) Double-staining for R-Ras and VEGFR2 shows an inverse correlation
(Spearman’s q: r	¼-0.821, P	¼0.023, R2 ¼0.563) between the number of R-Ras–expressing and VEGFR2-positive blood vessels. When a majority of
blood vessels has R-Ras expression, a majority of blood vessels are negative for VEGFR2 expression, whereas the VEGFR2 expression is opposite
when very few blood vessels express R-Ras. Scale	bars: 200 lm.
sents a novel therapeutic approach that may be capable of
addressing pathologic vascular permeability without simulta-
neously worsening the underlying pathobiology of the
disease— hypoxia.
The differences between the mechanisms of R-Ras  and
other antiangiogenic therapies are evidenced by a recent
report implicating activated Ras signaling as a key mediator of
pathologic neovascularization induced by many cytokines and
growth factors, including VEGF, in blinding neovascular eye
diseases.22 Westenskow et al.22 reported that aberrant Ras
signaling can be inhibited by a molecule called p120RasGAP.
The inhibitory function of p120RasGAP on Ras-driven retinal
neovascularization was shown to take place through the
inhibition of sprouting angiogenesis.22 In contrast, R-Ras
functions in the retina primarily to stabilize vasculature and
prevent leakage and does not inhibit sprouting angiogenesis in
OIR. The mechanistic differences between R-Ras and p120Ras-
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FIGURE 7. Vascular leakage is mainly from blood vessels that do not express R-Ras in human diabetic retinopathy. The preretinal membranes from
human diabetic retinopathy patients were either stained for CD31, double-stained for CD31 (green) and R-Ras (brown) or stained for HSA (brown).
(A) Blood vessels in preretinal membranes stained for endothelial cells (CD31, brown). (B) Double-staining of blood vessels (CD31, green) and R-Ras
(brown) expression. (C) Vascular leakage was determined by using an antibody against HSA (brown). Red boxes on figures on the left are presented
as high magnification pictures on the right. (B and C) No vascular leakage (restricted HSA staining only inside the neovessels) can be seen around
neovessels with strong R-Ras expression. Conversely, the blood vessels that do not express any R-Ras show aberrant vascular permeability around
them. Arrows	 represent R-Ras–negative blood vessels. Scale	bars	on the left represent 450 lm and 200 lm on the right.
GAP are  further  highlighted  by  the  fact that  p120RasGAP
actually inhibits R-Ras.50
R-Ras has recently been proposed as a master regulator of
transendothelial permeability in angiogenesis.15,21,51 Our
understanding of the molecular mechanisms by which R-Ras
exerts its biological effects on endothelial cells has increased
recently.15,48 It has been demonstrated that R-Ras suppresses
endothelial cells’ response to VEGF by inhibiting internaliza-
tion of VEGFR2 that is required for full activation of the
receptor49 as well as by inhibiting VEGFR2-p38MAPK-HSP27
signaling axis.51 However, the biological effects of R-Ras in
angiogenesis cannot be solely attributed to the inhibition of the
VEGF signaling because VEGF inhibitors have been shown to
function in OIR by inhibiting sprouting angiogenesis,36,37
whereas R-Ras is known to promote endothelial cell survival.20
In addition to the inhibition of VEGF, it has been demonstrated
that R-Ras forms a complex with Rab interactor 2 protein and
Rab5, and then this complex activate Rac1, which in turn
activates integrins to promote endothelial cell adhesion to
surrounding ECM.52,53 R-Ras also interacts with filamin A,
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which is crucial for maintaining of endothelial  barrier
function.54 Furthermore, actin-binding protein Girdin/GIV
regulates transendothelial permeability by controlling VE-
cadherin trafficking through R-Ras.48 In the present study, we
confirmed a previous finding that R-Ras is required for
recruitment of pericytes around endothelial cells,21 which is
crucial for blood vessel stabilization.41 In accordance with
previous studies on tumors, we demonstrated that R-Ras
deficiency reduces VE-cadherin expression in endothelial cells,
which may result in increased vessel leakiness in R-Ras–
deficient   mice.21
We demonstrate that angiogenic blood vessels, especially
immature VEGFR2þ vessels, show reduced expression of R-Ras
in human diabetic neovascular membranes, and the reduced R-
Ras expression correlates with increased vascular leakage from
the neovessels of human diabetic vasculature. We suggest that
reduced vascular R-Ras expression is a critical feature in the
pathogenesis of human diabetic retinopathy, especially in the
accumulation of retinal edema. Thus, R-Ras represents a
promising new therapeutic target to address angiogenesis-
related pathologic vascular permeability.
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